Table 8. Overall Survival profile by Log-Rank analysis.
| Factors | OS | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSCLC | ESOC | CRC | H&NC | GC | |||||||||||||||||
| OS (day) | 95% CI | p | OS (day) | 95% CI | p | OS (day) | 95% CI | p | OS (day) | 95% CI | p | OS (day) | 95% CI | p | |||||||
| General OS | 417 | 209 | 624.7 | 420 | 171 | 669 | 655 | 314 | 996 | 371 | 261 | 481 | 476 | 86 | 866 | ||||||
| Sex | Male | 549 | 85.6 | 1012 | 0.93 | 420 | 171 | 669 | NA | 1393 | 367 | 2419 | 0.38 | 457 | 314 | 600 | 0.07 | 476 | 28.9 | 923 | 0.54 |
| Female | 417 | . | . | NA | NA | NA | 525 | 291 | 759 | 290 | 173 | 407 | 298 | 0 | 703 | ||||||
| Age | <60y | 351 | 201 | 501.4 | 0.58 | . | . | . | 0.48 | 867 | 274 | 1460 | 0.83 | 457 | 354 | 560 | 0.01 | 476 | 0 | 1021 | 0.73 |
| ≥60y | 549 | 4.11 | 1094 | 270 | 18.4 | 522 | 643 | 481 | 805 | 228 | 166 | 290 | 298 | 0 | 612 | ||||||
| Surgery | YES | 417 | 0.197 | 420 | 181.7 | 658.3 | 0.832 | 525 | 293.7 | 756.7 | 0.21 | 388 | 280.9 | 495.1 | 0.42 | 476 | 139.3 | 812.7 | 0.44 | ||
| NO | 278 | 48.4 | 507.6 | . | . | . | 867 | 474.4 | 756.7 | 228 | 20.8 | 435.2 | 166 | . | . | ||||||
| Nimotuzumab frequency | ≤6 | 417 | 104 | 729.9 | 0.22 | 270 | 191 | 349 | 0.12 | 391 | 341 | 441 | 0.32 | 228 | 20.9 | 435 | 0.37 | 77 | . | . | 0.03 |
| >6 | 549 | 168 | 930.3 | . | . | . | 655 | 317 | 993 | 388 | 341 | 435 | 476 | . | . | ||||||
| Nimotuzumab doses (mg/w) | ≤200 | 278 | 9.14 | 546.9 | 0.99 | 270 | . | . | 0.67 | 270 | . | . | 0.94 | 334 | 67.7 | 600 | 0.93 | 77 | 23.1 | 131 | 0.00 |
| >200 | 417 | 254 | 579.7 | 420 | 180 | 660 | 420 | 180 | 660 | 388 | 280 | 496 | 476 | . | . | ||||||
Bold text indicates statistically significant (P-values <0.05)